| Bioactivity | Minretumomab (CC-49) is a mouse anti-TAG-72 (tumor-associated glycoprotein 72) monoclonal antibody and a radioimmunoconjugate. Minretumomab can be used for the research of cancer and radioimmunotherapy (RIT)[1][2]. |
| In Vivo | Minretumomab 和吉西他滨联合治疗在小鼠结肠癌模型中显示出抗肿瘤作用[1]。 |
| Name | Minretumomab |
| CAS | 195189-17-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Graves SS, et al. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3712-21. [2]. Sheikh N. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute. Curr Opin Mol Ther. 2003 Aug;5(4):428-32. |